SmileDirectClub: A True “Megatrends” IPO With Good Alternative Data Metrics

Taxes

Shutterstock, Inc.

The US IPO market continues to be very healthy, and we continue to publish our notes here on some of the more interesting companies coming to market: today’s post focuses on SmileDirectClub (proposed ticker SDC) but also do check out our recent posts on
Chewy
,
Slack
,
WeWork
,
Beyond Meat
, and
Pinterest
.

You might already be familiar with Invisalign (by Align Technology, a company with an almost twenty year history in the public markets): the clear plastic “braces” that have grown in popularity tremendously over the years for treatment of certain cases of malocclusion. From a client’s perspective, the main difference between ALGN and SDC is that SDC’s service does not require in-person visits to an orthodontist, and the lower cost for SDC. Looking at ALGN’s most recent 10-K filing, we can see that the company has grown revenue at a 27% CAGR since 2014, and finished 2018 with almost $2 billion in revenues.       

There is a more recent crop of entrants in the clear aligners space, the most notable of which is SmileDirect. We read the S-1 and the S-1/A with great interest because SmileDirect is at the intersection of several mega-trends. This is not hype: we really mean this. SmileDirect has both the sales growth and, by now, the sales volume to prove it. Revenues grew 7x from 2016 to 2017, then almost 3x’ed from 2017 to 2018, and is now on track to more than double in 2019. Patients (or, if you prefer the company’s more modern word choice, “members”) are now at over 700k cumulatively.  

By way of comparison, it took ALGN from 2010 to 2014 double from $387 million in revenues to $761 million while it looks like it will take SDC just one year to double from roughly the same starting point of approximately $400 million in revenues. 

SDC’s explosive growth has been, in our view, powered by true megatrends. These megatrends are:

  • Direct to Consumer (DTC) with subscription and omnichannel characteristics
  • Healthcare delivery innovations
  • Healthcare access and affordability
  • Beauty

And SmileDirect appears to be winning across the board with a vertical integration of advanced technology, in-house financing, high skill offshoring/regulatory arb, and good marketing.  

The customer journey at SDC begins with either a visit to one of 300+ “SmileShops” (co-located at CVS and Walgreens in the US; also UK, Canada, PR, Australia) for a scan, or with an at-home impressions kit. The company staff in Costa Rica (orthodontists and technicians) then prepares a treatment plan, which the customer approves, with the final approval (prescription) happening through a state-licensed US-based orthodontist. The sequence of aligners is shipped at once from a US facility (one in TN, one being built in TX), with periodic check-ins required. The major benefits, as described in the S-1, are (1) lower cost (list price of under $2,000 vs. $5,000-$8,000); (2) expanded access to treatment through teledentistry (no office visits; the company also states that fewer than 40% of US counties have orthodontists); (3) shorter time frame for treatment (5-10 months vs. 12-24 months, though it is unclear how much of this is due to case specifics), and (4) captive financing (with recently expanded “in network” access with two major US insurers). 

We see the “megatrends” every step of the way: DTC infrastructure enables direct relationships, omnichannel presence increases reach, and, obviously, the product/service is 100% personalized. The combination of DTC and lower cost, high skilled operations expand access by lowering cost (though two state dental boards, in AL and GA, have taken issue with the latter- we see it as a bit of a regulatory arbitrage to have the last “touchpoint” done in the US-, and SDC is currently suing both entities). There is quite a bit more from the management presentation on the total market potential and other aspect on Retail Roadshow (link generally available prior to the actual offering). The management story is very interesting: the CEO David Katzman has a long history of involvement in disruptive services (Quicken Loans being the most famous but also a direct lenses business sold to the leader in that space, and an earlier venture acquired by Home Depot). The subscription element is the growing retainers business post-treatment (a substantial percentage of patients are people who had braces years ago but whose teeth moved back). 

The in-house financing part is also an interesting aspect of the operation: the company offers a “no credit check” financing option at 17% APR ($250 downpayment, which covers the cost of the aligners, and then $85 monthly payments over 24 months). The default rate is under 10%. The most recent data is that 65% of the customers use SmilePay, indicating both the importance of having an affordable and transparent option for discretionary procedures. The CEO on the roadshow said that prior experience with third-party financing was negative (too high drop-offs). The complications around the consumer financing regulation are an additional “moat” for the model. 

We were also interested in the marketing aspect of this remarkable growth story: the company says that it has around five million unique visitors to its website every month, and that it is able to convert about 1% of them to new customers, up from 0.5% in 2016. The company has also been improving its appointment show rates at the SmileShops and the acceptance of the impression kits. The company also lists over 300,000 followers on Instagram and over 500,000 likes on Facebook, as of June 2019. These numbers as of right now are over 360,000 followers on Instagram (20% growth in three months) and 531,000 Likes on Facebook. The company also boost very high review ratings (4.9/5.0), and 57 Net Promoter Score (extraordinarily high, on par with Zappos, per the roadshow linked above). 

Since we incorporate alternative data sets very heavily in our platform (see our recent webinar and white paper on the topic), we were interested in seeing how the data looks. 

We are seeing very good long-term trends for the broad search trends for clear aligners, as a search topic (a broader collection of searches, versus a specific term). This is a valid signal as aligners are a high investment purchase, both in terms of money and in terms of time (or, as the company calls it, a “highly considered purchase” with long lead cycles: the roadshow presentation mentioned that a lot of customers are 7-12 month leads). We can also see the January spikes in search interest, similar to fitness interest and other self-improvement topics. (interactive chart link

The customer journey might start with broad searches but then a lot of the research is done on the companies’ websites. We pulled the Alexa data for SDC, ALGN, as well as the DTC competitors that SDC lists in the S-1: CandidCo, SnapCorrect and SmileLove. We can clearly see that overall industry web traffic has been growing, and that SDC is now bigger than ALGN. We are showing 30-day moving averages (Interactive chart link)

Perhaps most interesting to us is the web traffic “market share” that SDC has vs. the incumbent leader ALGN build from the overall chart above (what percentage of the industry traffic goes to the two major players). We can see that SDC is now consistently capturing more traffic vs. ALGN, likely indicative of future real share growth. (Interactive chart link

We fully expect that this offering will be very popular given the defensible growth characteristic of the business, and the current investors’ relaxed attitude around governance/related issues (not the topic of this piece but SDC is a JOBS Act IPO, with multi-class shares, classified board, numerous related party transactions including a Tax Receivable Agreement, underwriter conflicts, corporate structure, and quite a bit more). 

Articles You May Like

Japan bucks private equity slowdown in Asia Pacific with deal value soaring 183% last year
Amgen wants in on the booming weight loss drug market — and it’s taking a different approach
‘Gray divorce’ has doubled since the ’90s — and the financial risk is high for women
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
Larry Fink Re-Focuses Stakeholder Capitalism On Securing Employee Retirement

Leave a Reply

Your email address will not be published. Required fields are marked *